In patients with benign prostate hyperplasia who received tamsulosin 0.2 mg for more than 4 weeks, the improvement of the lower urinary tract symptom terazosin 5 mg administered for 12 weeks

Dankook Univeristy Hospital0 个研究点目标入组 51 人开始时间: 待定最近更新: 2020年1月14日

试验速览

暂无简介。

•1) Male over 40 years
•2) Patients diagnosed with benign prostatic hyperplasia
•3) Patients have an IPSS score of at least 8
•4) Patients who have been prescribed Tamsulosin 0.2mg for more than 4 weeks but have no significant improvement in IPSS score or maximum urinary velocity (Qmax)
•5) Patients who voluntarily decided to participate in this study and agreed in writing to the subject consent form

•1) Patients with hypersensitivity to a-blocker family drugs.
•2) Patients who are taking cholinergic drugs, diuretics, or ß3-antagonists.
•3) Patients with urination disorders due to obvious causes other than benign prostatic hyperplasia.
•4) Patients with neurogenic bladder disorders.
•5) Patients with urinary tract infections (midstream urine culture> 100,000 colonies/mL)
•6) Patients with clinically significant circulatory disorders (myocardial infarction, heart failure, angina pectoris, cardiac arrhythmias, pacemaker use, orthostatic hypotension, uncontrolled hypotension)
•7) Participants in other interventions within 6 months of screening
•8) Patients who are inappropriate to participate in research as judged by other research managers or researchers

发起方

Dankook Univeristy Hospital